Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 336

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 336
---
 of Contents

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(Unaudited) 

(In thousands, except share and per share data)

 Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Revenue:Product sales, net$127,785 $77,760 $239,370 $146,677 License and other revenue— 115 — 420 Total revenue127,785 77,875 239,370 147,097 Operating expenses:Cost of sales23,421 20,227 46,439 38,057 Research and development46,067 32,672 92,111 64,894 Selling, general and administrative63,286 49,208 120,992 94,846 Total operating expenses132,774 102,107 259,542 197,797 Loss from operations(4,989)(24,232)(20,172)(50,700)Other income (expense):Interest income3,033 3,486 6,056 7,119 Interest expense(3,589)(3,569)(7,185)(7,146)Other income, net86 312 2,194 2,069 Net loss before provision for income taxes(5,459)(24,003)(19,107)(48,658)Provision for income taxes402 635 1,431 1,259 Net loss$(5,861)$(24,638)$(20,538)$(49,917)Net loss per share, basic and diluted$(0.12)$(0.52)$(0.42)$(1.06)Weighted-average shares of common stock outstanding, basic and diluted49,726,82347,235,08049,310,25547,081,315

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

Table of Contents

Mirum Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

 Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Net loss$(5,861)$(24,638)$(20,538)$(49,917)Other comprehensive income (loss):Unrealized (loss) gain on available-for-sale investments(12)7 (35)7 Cum